Compare Cassava Sciences Inc (FLNA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nomura Holdings Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Nomura Holdings Inc trades at $10.05 (market cap $29.38B). The key difference: Nomura Holdings Inc is far larger — about 552.9× Cassava Sciences Inc's market cap, and Nomura Holdings Inc pays a 3.23% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NMR | |
|---|---|---|
Market Cap | $53.14M | $29.38B |
Sector | Health | Financials |
52-Week High | $4.64 | $10.04 |
52-Week Low | $1.09 | $6.30 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Nomura Holdings (NMR) trades at $9.85, up 1.03% with a bullish technical outlook from moving averages. The stock shows strong fundamentals with a P/E of 13.65, net income margin of 19.66%, and record annual profit in 2025. Recent news highlights expansion in wholesale revenue and strategic acquisitions, including a U.S. fund management push and digital asset subsidiary progress.
Outlook is positive due to valuation discounts versus peers and ROE expansion potential, but risks include earnings misses in recent quarters and rising debt-to-asset ratios. Analysts are mixed with 33% buy ratings, suggesting cautious optimism amid integration costs from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
